15 March 2024
15 March 2024
In the trial, nesvategrast was found to be safe and well-tolerated in DR patients.
In the trial, one patient on the 75mg/day dosage of NXP800 achieved a partial response.
In the initial stage, the trial will assess the tolerability, safety, and pharmacokinetic profile of NUV-1511.
An Independent Safety Committee will review the comprehensive data from the four-subject cohort in the trial.
SciSparc is evaluating its SCI-210 compound in children and adolescents with ASD over a 24-week period.
Exact Sciences submitted a pre-market approval application for the device to the FDA in December 2023.
Empros Pharma is hopeful that if approved, its combination therapy could become a second-line therapy for obesity.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
